Business Context and Reporting Period
This Form 8-K Current Report was filed by Aerovate Therapeutics, Inc. (not Jade Biosciences, Inc.) on January 8, 2024. The registrant is a Delaware corporation with its principal executive offices in Waltham, Massachusetts. The company is classified as an emerging growth company and its common stock trades on The Nasdaq Global Market under the symbol AVTE.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the furnishing of a corporate presentation and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing is procedural, intended to satisfy Regulation FD disclosure obligations regarding a corporate presentation.
Guidance, Outlook, and Management Commentary
- Regulation FD Disclosure: The Company is furnishing a corporate presentation (Exhibit 99.1) intended for use in meetings with investors beginning January 8, 2024.
- Availability: The presentation is available on the Company's website under the "Events & Presentations" section.
- Legal Status: The information in this Item 7.01 and Exhibit 99.1 is furnished, not "filed," and is not subject to the liabilities of Section 18 of the Exchange Act unless expressly incorporated by reference.
Investor Verification Checklist
- Verify the correct registrant name is Aerovate Therapeutics, Inc. (AVTE), as the input metadata incorrectly referenced Jade Biosciences, Inc.
- Access the attached Exhibit 99.1 (Corporate Presentation) on the investor relations website for actual business updates and strategic outlook.
- Confirm that no financial data is contained within this specific 8-K filing; refer to the most recent 10-K or 10-Q for financial metrics.
- Note the company's status as an emerging growth company, which may affect financial reporting requirements.